A detailed history of Allianz Se transactions in Cure Vac N.V. stock. As of the latest transaction made, Allianz Se holds 90 shares of CVAC stock, worth $330. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90
Holding current value
$330
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

BUY
$2.49 - $3.41 $224 - $306
90 New
90 $307,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $688M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Allianz Se Portfolio

Follow Allianz Se and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Se, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Se with notifications on news.